This duality poses both challenges and opportunities: inhibiting Nrf2 may sensitize cancer cells to ferroptosis inducers, whereas activating Nrf2 may offer protection in non-neoplastic diseases driven by ferroptosis and oxidative stress (8). Here, NFE2L2 is linked to neoplasm.